Azitra, Inc.
ASE: AZTRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Azitra, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get AZTR Z-Score →About Azitra, Inc.
Healthcare
Biotechnology
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
📊 Fundamental Analysis
Azitra, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -230.7%, which indicates that capital utilization is currently under pressure.
At a current price of $0.23, AZTR currently trades near the bottom of its 52-week range (5%), indicating potential value or weakness (Range: $0.10 - $2.67).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$3.68M
Trailing P/E
--
Forward P/E
-0.44
Beta (5Y)
-2.17
52W High
$2.67
52W Low
$0.10
Avg Volume
12.95M
Day High
Day Low